CN-121987620-A - Application of dihydrocoumarin in preparation of inflammatory bowel disease products

Abstract

The invention discloses application of dihydrocoumarin in preparation of inflammatory bowel disease products, and belongs to the technical field of medicines. The technical problems to be solved are that the existing inflammatory bowel disease treatment drug has obvious side effect, is easy to generate drug resistance and has high disease recurrence rate, the specific effect of the dihydrocoumarin in inflammatory bowel disease intervention is not clear, and the related application is not effectively developed. The technical scheme is characterized by providing application of the dihydrocoumarin in preparing inflammatory bowel disease medicines, health-care foods and functional foods, and intervening an inflammatory bowel disease model by a proper administration mode, improving weight loss, abnormal feces, colon shortening and pathological damage of colon tissues of model animals, reducing disease activity indexes, thereby realizing the intervention effect on the inflammatory bowel disease.

Inventors

• SUN SHIHAO
• LUO YUFENG
• ZHOU YING
• YANG YINAN
• GENG HUIJUN
• YUAN MENGMENG
• YANG PEIWEN
• ZHANG DONGHAO
• Qi Guihong
• LI PENG

Assignees

• 北京生命科技研究院有限公司

Dates

Publication Date

20260508

Application Date

20260401

Claims (10)

1. 1. Use of dihydrocoumarin in the preparation of a product for the prevention and/or treatment of inflammatory bowel disease.
2. 2. The use according to claim 1, wherein the inflammatory bowel disease comprises ulcerative colitis or crohn's disease.
3. 3. The use according to claim 2, wherein the inflammatory bowel disease is ulcerative colitis.
4. 4. The use according to claim 1, wherein the product comprises dihydrocoumarin as the sole or main active ingredient, and the product comprises a medicament, a health food or a functional food.
5. 5. The use according to claim 1, wherein the product further comprises pharmaceutically, food acceptable excipients.
6. 6. The use according to claim 5, wherein the pharmaceutically, food acceptable excipients are selected from one or more of fillers, binders, disintegrants, lubricants or preservatives.
7. 7. The use according to claim 6, wherein the filler is one or more of starch, lactose or microcrystalline cellulose; the adhesive is one or more of hypromellose or povidone; the disintegrating agent is one or more of sodium carboxymethyl starch or crospovidone; the lubricant is one or more of magnesium stearate or talcum powder; The preservative is one or more of sodium benzoate or potassium sorbate.
8. 8. The use according to any one of claims 1 to 7, wherein the product is in the form of a tablet, capsule, granule, suspension, powder, injection, suppository, gel or cream.
9. 9. The use according to any one of claims 1 to 7, wherein the mode of administration of the product is selected from gastrointestinal administration or injection administration.
10. 10. The use according to claim 9, wherein the gastrointestinal administration is a gastric administration, an oral administration or a rectal administration, and the injection administration is subcutaneous injection, intravenous injection, intramuscular injection or intraperitoneal injection.

Description

Application of dihydrocoumarin in preparation of inflammatory bowel disease products Technical Field The invention belongs to the technical field of medicines, relates to a product derived from a natural product and application thereof, and in particular relates to application of dihydrocoumarin in preparation of inflammatory bowel disease products. Background Intestinal inflammatory diseases (Inflammatory Bowel Disease, IBD) are a class of chronic recurrent digestive system diseases characterized by a sustained inflammatory response of the intestinal mucosa, mainly comprising ulcerative colitis (Ulcerative Colitis, UC) and Crohn's Disease (CD), whose onset is closely related to impaired intestinal barrier function, unbalanced immune response and abnormal activation of inflammatory signaling pathways. In clinic, patients often show symptoms such as diarrhea, mucopurulent bloody stool, abdominal pain, weight reduction and the like, the disease is repeated and the lasting is difficult to heal, not only the quality of life is seriously affected, but also the serious complications such as colon perforation, canceration and the like can be caused. Currently, clinical treatment of IBD is centered on the inhibition of inflammation and symptomatic relief, and common drugs include glucocorticoids, 5-aminosalicylic acid, immunosuppressants, and the like. However, the traditional treatment schemes have obvious limitations that the long-term use of the glucocorticoid is easy to cause adverse reactions such as osteoporosis, liver and kidney function injury and the like, the 5-aminosalicylic acid medicament has limited curative effect on moderately severe patients, and the immunosuppressant can reduce the immunity of the patients and increase the infection risk. Meanwhile, partial patients have weakened curative effect or drug resistance in the treatment process, so that the disease recurrence rate is high, and the clinical requirements for safe, efficient and sustainable intervention are difficult to meet. In the basic research and drug development of IBD, animal models are a key tool for assessing the efficacy of interventions. The mouse colon inflammation model induced by dextran sodium sulfate (Dextran Sodium Sulfate, DSS) is widely applied to activity screening and effect verification of candidate intervention substances because of simple operation, short modeling period and high coincidence of pathological features (such as intestinal mucosa injury, inflammatory cell infiltration, weight reduction, colon shortening and disease activity index rise) with human IBD. The model can intuitively monitor the improvement effect of the intervention substances on the weight change, fecal character, fecal occult blood, colon morphology and tissue pathological damage of the mice, and provides reliable experimental basis for subsequent application. The natural product-derived small molecule compound gradually becomes a research hotspot in the field of IBD intervention by virtue of structural diversity, good biocompatibility and the like. The dihydrocoumarin is an important derivative form of coumarin compounds, has stable physicochemical properties, has a certain anti-inflammatory related biological activity, and has potential value for developing intestinal inflammation intervention substances. However, the lack of systematic studies on dihydrocoumarin in DSS-induced intestinal inflammation models in the prior art has not been clear about the specific intervention effect, the appropriate dosage and the effect on the relevant phenotypes of intestinal inflammation (such as weight maintenance, colon morphology protection, tissue injury repair, etc.), nor has the relevant applications been effectively developed. The related patent documents: The publication in China, publication No. CN111467327A, discloses application of Jiang Xitong A in preparing a medicament for preventing and treating colonitis, and has the core advantages of remarkably improving clinical symptoms such as loose stool, bloody stool and the like of colonitis mice, reducing colonic atrophy, reducing colonic thickness, enhancing intestinal barrier function and having no obvious side effect. The publication No. CN118542877A relates to the application of glycyrrhizic acid or salt or ester thereof in preparing medicines for treating inflammatory bowel disease, and the application realizes the improvement of inflammation and the repair of intestinal barrier by selectively inhibiting the local 11 beta-HSD 1 enzyme activity of colon of mice with enteritis induced by DSS and improving the local glucocorticoid level of intestinal tissues. The prior art represented by the foregoing documents has at least the following technical problems or drawbacks that have not been solved: (1) The lack of systematic experimental verification of the intervention effect of Dihydrocoumarin (DCN) in intestinal inflammation, whether it can improve the phenotype associated with DSS-induced col